Clinical Trial Update: A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

View source ↗

Summary

Pfizer-sponsored trial evaluating first- and later-line therapies for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma | Status: COMPLETED